Latest News for: Executive nda

Edit

HLB's US subsidiary promotes efficacy of liver cancer drug Rivoceranib

Korea Times 23 Mar 2023
This comes as part of the Korean biotech company's efforts to promote the drug ahead of applying for new drug application (NDA) with the U.S ... Executives of Elevar participated in the symposium, Tuesday, co-hosted by Korea's Ministry of Food and Drug Safety and the Korea American Society in Biotech and Pharmaceuticals (KASBP).
Edit

Akufo-Addo appoints Zakaria Iddi as Deputy CEO in charge of Project at NDA

Modern Ghana 22 Mar 2023
The President, Nana Addo Dankwa Akufu-Addo has appointed Mr. Zakaria Iddi as Deputy Chief Executive Officer (Deputy CEO) in charge of projects at the Northern Development Authority (NDA) In a letter signed by the Chief of Staff Hon ... .
Edit

Lumicell Submits New Drug Application for LUMISIGHT™ Optical Imaging Agent to U.S. FDA for Intraoperative ...

Hastings Tribune 21 Mar 2023
Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies for cancer surgery, today announced a New Drug Application (NDA) for its LUMISIGHT™ Optical Imaging Agent has been submitted to the U.S ...Submission of the LUMISIGHT NDA is a significant step toward achieving this goal.
Edit

Non-disclosure agreements and the trinity of obligations: what parties need to know

B & FT Online 15 Mar 2023
Therefore, the intent of this article is to discuss the scope of Non-Disclosure Agreements and the resulting trinity of obligations as a way of fostering a clearer understanding and compliance with an executed NDA ... When to execute an NDA?.
Edit

OSP ordered to file statement in Charles Bissue case within 14 days

Ghana Business News 14 Mar 2023
Charles Bissue ... “I have just been appointed to fill that void,” he told the court ... Additionally, Plaintiff’s counsel the OSP has resorted to using the ongoing judicial process in respect of its prosecution of the former Chief Executive Officer of the Northern Development Authority (NDA) and others, as an excuse for its failures ... Source. GNA ....
Edit

Condor Gold Provides an Update on the Sale of Assets

Eagle-Tribune 13 Mar 2023
Three formal expressions of interest including 2 non-binding offers (subject to further due diligence) have been received by the Company and further offers are expected as nine companies are under a Non-Disclosure Agreement (NDA). Mark Child, Chief Executive of Condor Gold, commented..
Edit

CORRECTION FROM SOURCE: Condor Gold Provides an Update on the Sale of Assets

Eagle-Tribune 13 Mar 2023
Three formal expressions of interest including 2 non-binding offers (subject to further due diligence) have been received by the Company and further offers are expected as nine companies are under a Non-Disclosure Agreement (NDA). Mark Child, Chief Executive of Condor Gold, commented..
Edit

Galera Announces Presentation of Supplemental Analysis of Phase 3 ROMAN Trial at European ...

Eagle-Tribune 10 Mar 2023
Galera’s New Drug Application (NDA) in the U.S ... "We are pleased to present at ECHNO the results of the Phase 3 ROMAN trial, including a net treatment benefit analysis submitted as part of Galera’s NDA,” said Mel Sorensen, M.D., President and Chief Executive Officer of Galera Therapeutics.
Edit

Aldeyra Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

Pharmiweb 09 Mar 2023
“Now with Priority Review Designation for the treatment of primary vitreoretinal lymphoma, ADX‑2191 joins reproxalap as the second investigational drug candidate at Aldeyra under NDA review at the U.S ... Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra.
Edit

SpringWorks Therapeutics Announces New England Journal of Medicine Publication of Phase 3 DeFi ...

Eagle-Tribune 08 Mar 2023
We are very pleased that nirogacestat provided benefit across all prespecified subgroups in the study, which underscores the potential to broadly serve desmoid tumor patients regardless of tumor location, prior treatments or surgery, or genetic mutation,” said Saqib Islam, Chief Executive Officer of SpringWorks.
Edit

Milestone Pharmaceuticals Progresses Clinical and Regulatory Activities for Etripamil in Patients with Paroxysmal Supraventricular Tachycardia

Victoria Advocate 06 Mar 2023
"With the completion of the NODE-303 and RAPID-extension studies and the recent feedback from the FDA, we are confident we have the necessary data for an NDA submission in the third quarter of 2023," said Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals.
Edit

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results

Eagle-Tribune 06 Mar 2023
“We continue to execute across all aspects of our business, highlighted by the FDA’s recent acceptance of the filing of the resubmission of our NDA for VP-102, which is being developed for the treatment of molluscum contagiosum,” said Ted White, Verrica’s President and Chief Executive Officer.

Most Viewed

×